pramipexol (pramipexole)

Subscribe to Selected New Research on pramipexol

237 relevant articles (52 outcomes, 70 trials/studies) found for this Drug

Description: RN given refers to (S)-isomer

Also Known As:

pramipexole; Mirapex; (+)2-amino-4,5,6,7-tetrahydro-6-L-propylaminobenzothiazole dihydrochloride; 2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole; 2-amino-6-propylaminotetrahydrobenzothiazole; SND 919CL2x; SND-919; SND-919CL2x; SND919CL2x; pramipexol dihydrobromide, (+-)-isomer; pramipexol dihydrochloride, (S)-isomer; pramipexol, (+-)-isomer; pramipexol, (R)-isomer; 2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N6-propyl-, (S)-

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 23

1-Ring Heterocyclic Compounds

2-Ring Heterocyclic Compounds

Benzothiazoles: 10

pramipexol: 237

Experts

1.	Parkinson Study Group: 7 articles (03/2007 - 10/2000)
2.	Oertel, Wolfgang H: 6 articles (06/2007 - 01/2004)
3.	Koester, Juergen: 5 articles (01/2007 - 01/2005)
4.	Holloway, Robert G: 5 articles (01/2006 - 02/2002)
5.	Montplaisir, J: 3 articles (12/2006 - 05/2000)
6.	Reess, Juergen: 3 articles (01/2007 - 08/2006)
7.	Dick, Andrew W: 3 articles (01/2006 - 09/2004)
8.	Noyes, Katia: 3 articles (01/2006 - 09/2004)
9.	Oertel, W H: 3 articles (06/2002 - 05/2000)
10.	Reichmann, Heinz: 3 articles (10/2006 - 01/2003)

Related Diseases

1.	Parkinson Disease (Parkinson's Disease) 05/01/2005 - "In addition, pramipexole significantly improved the subitems motivation/initiative and depression in a subpopulation with increased Unified Parkinson's Disease Rating Scale I scores at the time of inclusion" 07/11/1997 - "In the present study, pramipexole, a D3-preferring DA agonist effective in treating Parkinson's disease, excited type II anterior CN neurons" 05/01/2006 - "Despite the absence of motor complications, the pramipexole recipients showed improvement on the Unified Parkinson's Disease Rating Scale (UPDRS) motor subscore" 07/09/1997 - "Safety and efficacy of pramipexole in early Parkinson disease" 01/01/2005 - "In the present study, the authors assessed for the first time frequency of anhedonia in patients with idiopathic Parkinson's disease (N = 657) and the relationship of anhedonia and parkinsonian motor deficits during treatment with pramipexole" Get all the results and reference details, order at left...
2.	Restless Legs Syndrome (Restless Legs) 01/20/2007 - "Fifty-one patients suffering from idiopathic restless legs syndrome underwent monotherapy with pramipexole in daily doses of 0.25 to 1.0 mg. Therapeutic efficacy was evaluated using three tools, i.e" 01/15/2007 - "Efficacy of pramipexole in restless legs syndrome: a six-week, multicenter, randomized, double-blind study (effect-RLS study)." 03/23/1999 - "Restless legs syndrome improved by pramipexole: a double-blind randomized trial." 08/01/2007 - "First night efficacy of pramipexole in restless legs syndrome and periodic leg movements." 01/15/2007 - "We evaluated the efficacy of pramipexole versus placebo in restless legs syndrome (RLS) for 6 weeks" Get all the results and reference details, order at left...
3.	Tremor (Tremors) 05/01/2000 - "In another study pramipexole has been shown to be significantly superior to placebo with an improvement in tremor score by 48% (vs. 13% in the placebo group)" 09/01/1999 - "The patients were drawn from a larger placebo-controlled, double-blind, randomized trial, which was not originally designed to investigate the effect of pramipexole on tremor" 01/01/2006 - "The main reasons for switching to pramipexole (anti-tremor effect, anti-depressive/anti-anhedonic effect) as given by the physicians at baseline came up to expectations" 05/01/2005 - "Patients with pronounced resting tremor derived a clear benefit from pramipexole treatment compared with placebo" 10/01/2003 - "Three weeks after initiation of pramipexol, the tremor artefact was no longer visible on ECG" Get all the results and reference details, order at left...
4.	Dyskinesias (Dyskinesia) 07/01/2004 - "RESULTS: Initial pramipexole treatment resulted in a significant reduction in the risk of developing dyskinesias (24.5% vs 54%; hazard ratio, 0.37; 95% confidence interval [CI], 0.25-0.56; P<.001) and wearing off (47% vs 62.7%; hazard ratio, 0.68; 95% CI, 0.49-0.63; P =.02)" 04/01/2008 - "This review addresses the literature concerning pramipexole's efficacy in treating motor and non-motor symptoms in PD, its impact on the development of dyskinesias and response fluctuations, the issue of neuroprotection, and the risk for developing adverse events such as increased somnolence, attacks of sudden onset of sleep, cardiac valvulopathy and impulse control disturbances." 01/01/2008 - "Furthermore, in laboratory studies pramipexole has proved to exert neuroprotector effects and its use in clinical practice from the early stages of the disease has been related to a delay in the appearance of motor complications (fluctuations and dyskinesias)" 01/01/2000 - "No significant changes were noted in a dyskinesia rating scale in any of the 4 studies, but dyskinesia as an adverse event was reported more frequently with pramipexole" 12/01/2006 - "Pramipexole treatment was associated with later occurrence of dyskinesias" Get all the results and reference details, order at left...
5.	Bipolar Disorder (Mania) 03/01/2004 - "CONCLUSIONS: Pramipexole was a safe and effective antidepressant among patients with bipolar depression" 03/01/2004 - "The authors conducted a preliminary randomized, placebo-controlled trial to determine the safety and antidepressant efficacy of pramipexole in treatment-resistant bipolar depression" 01/01/2007 - "Recently published placebo-controlled trials in small patient groups implicate that pramipexole is effective as additional treatment to mood stabilizers in I and II bipolar depression." 03/01/2004 - "Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression." 02/01/2007 - "A case of mania following the use of pramipexole." Get all the results and reference details, order at left...
78 Diseases and 237 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Dopamine Agonists (Dopamine Agonist)
2.	Levodopa (L Dopa)
3.	ropinirole (Requip)
4.	Pergolide (Permax)
5.	cabergoline
6.	Dopamine (Intropin)
7.	N 0437
8.	Bromocriptine (Parlodel)
9.	Dopamine Receptors (Dopamine Receptor)
10.	Antidepressive Agents (Antidepressants)
81 Drugs and Important Bio-Agents and 170 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Activities of Daily Living (ADL)
2.	Analgesia
3.	Renal Dialysis (Hemodialysis)
3 Therapies and Procedures and 11 more articles analyzed in the Research Interface, order at left...

Research Interface Subscription

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Searches
2 clicks from Disease to Drug to Evidence
Trial references
All the Positive Outcomes
Drug and Therapy searches
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface Subscription

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>